For immunochemical detection of macroH2A1 and macroH2A2
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Histone MacroH2A1/MacroH2A2 (C-Term) Monoclonal Antibody (Clone RM248)

Item No. 32176

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Immunogen
Peptide from the C-terminal region of human macroH2A1
Clone Designation
RM248
Formulation (Request formulation change)
100 µg of protein A-affinity purified monoclonal antibody
Storage Buffer
PBS with 50% glycerol, 1% BSA, and 0.09% sodium azide
Host
Rabbit
Isotype
IgG
Applications
ELISA, ICC, multiplex-based assays, WB
Cross Reactivity
(+) MacroH2A1(+) MacroH2A2, independent of PTMs(-) Other histones
Species Reactivity
(+) Vertebrates
Shipping & Storage Information
Storage
-20°C
Shipping
Wet ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    100 µg

    $500

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    MacroH2A proteins are variant histones that are enriched on inactivated X chromosomes and have roles in the maintenance of nuclear organization and heterochromatin architecture.1,2,3 MacroH2A1 is encoded by MACROH2A1 and can exist as two isoforms, macroH2A1.1 and macroH2A1.2, produced by alternative splicing, and macroH2A2 is encoded by MACROH2A2.2 MacroH2As are comprised of a histone fold, which is approximately 65% identical to canonical histone H2A, a basic linker, and a C-terminal non-histone macrodomain, which is unique to macroH2As and protrudes from the nucleosome core to recruit various co-factors.3,1,2 The non-histone region of macroH2A2 is 68% identical to that of macroH2A1.2, whereas the macrodomain of macroH2A1.1 is unique in that it can bind to ADP-ribose and ADP-ribosylated proteins.2,3 Low levels of macroH2A1.1 are associated with poor prognosis in patients with lung or colon cancer, and loss of macroH2A2 expression is associated with earlier recurrence of lesions in patients with anal intraepithelial neoplasia (AIN).3,4 MacroH2A1.2 expression is increased in highly proliferative cancer cell lines, but it can act as a tumor suppressor in melanoma and bladder cancer, indicating that its role in cancer is context-dependent. Cayman's Histone MacroH2A1/MacroH2A2 (C-Term) Monoclonal Antibody (Clone RM248) can be used for ELISA, immunocytochemistry (ICC), multiplex-based assay, and Western blot (WB) applications. The antibody recognizes the C-terminus of macroH2A1 and macroH2A2 independent of post-translational modifications (PTMs).

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Ruiz, P.D., and Gamble, M.J. MacroH2A1 chromatin specification requires its docking domain and acetylation of H2B lysine 20. Nat. Commun. 9(1), 5143 (2018).

    2. Costanzi, C., and Pehrson, J.R. MACROH2A2, a new member of the MARCOH2A core histone family. The Journal of Biological Chemisty 276(24), 21776-21784 (2001).

    3. Corujo, D., and Buschbeck, M. Post-translational modifications of H2A histone variants and their role in cancer. Cancers (Basel) 10(3), 59 (2018).

    4. Giallongo, S., Lo Re, O., and Vinciguerra, M. Macro histone variants: Emerging rheostats of gastrointestinal cancers. Cancers (Basel) 11(5), 676 (2019).